AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01319227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip replacement
Description: Hip arthroplasty with uncemented components
Study NCT04188483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
Study NCT00803959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UDS
Description: Urodynamics
Study NCT01182233 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Skeletal Irradiation
Description: Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
Study NCT01519583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Intervention
Description: Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
Study NCT01519583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Pedometry
Description: Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
Study NCT01519583 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Maintain usual physical activity, and return for follow-up measures.
Study NCT03765073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels
Study NCT03765073 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control
Study NCT01566942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
Study NCT02481271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice
Study NCT02481271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery
Study NCT01639066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir 300mg daily Oral
Study NCT01639066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 1 mg daily Oral
Study NCT01639066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 300mg daily Oral
Study NCT00811824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and dietary change
Description: 6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
Study NCT00811824 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity and dietary change
Description: 6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
Study NCT00402532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Initial dosage 2 x 0.75 mg/d
Study NCT00402532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolatmofetil
Description: Initial dosage 2 x 500 mg/d intravenous
Study NCT02967913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder flap
Description: bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
Study NCT04929366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic dialysis followed with routine dialysis
Description: Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)
Study NCT04929366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine dialysis followed with hypothermic dialysis
Description: Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)
Study NCT00697541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.18% COL-118 facial gel (1.8 mg brimonidine)
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
Study NCT00697541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
Description: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
Study NCT00697541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced Eye Relief
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
Study NCT00697541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL-118 facial gel vehicle
Description: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
Study NCT01577849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: administration of Vitamin D3 24,000 IU
Study NCT01577849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R206
Description: administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
Study NCT01217385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DOSI
Description: Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
Study NCT02584894 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS 1Hz
Description: trauma exposure + repeated transcranial magnetic stimulation at 1Hz
Study NCT02584894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS 10Hz
Description: trauma exposure + repeated transcranial magnetic stimulation at 10Hz
Study NCT02584894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoneurological assessment
Description: psychoneurological assessment
Study NCT02584894 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: psychoneurological assessment
Description: psychoneurological assessment
Study NCT02584894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conductivity meter
Description: electrodermal conductance measure
Study NCT02584894 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conductivity meter
Description: electrodermal conductance measure
Study NCT02584894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrocardiogram
Description: heart rate measure
Study NCT02584894 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electrocardiogram
Description: heart rate measure
Study NCT02611505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
Study NCT00535847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study NCT00535847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT00535847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2a
Description: Solution for Injection
Study NCT03817411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telatinib
Description: 300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
Study NCT03817411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
Study NCT03817411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
Study NCT03817411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
Study NCT03817411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
Study NCT03817411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
Study NCT02205905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C PER977
Description: Open-label, single dose
Study NCT01253174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)
Description: single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
Study NCT01253174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)
Description: single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
Study NCT01253174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-5-MTHF Ca 0.451 mg (Metafolin)
Description: single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
Study NCT03706859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet inflation pressure
Description: Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
Study NCT03706859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic tourniquet inflation pressure
Description: Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
Study NCT00665587 — intervention group
Intervention type: PROCEDURE
Intervention: Cox-MAZE III
Description: Maze procedure according to standards of the department
Study NCT03475199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FabLife
Description: * A personnalized dietary program depending on the patient's phenotype and genotype~* The daily intake of a dietary supplement, developped in the context of male infertility.
Study NCT01424046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin glargine
Description: Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
Study NCT01424046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
Study NCT01815606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy with 19 gauge needle
Description: biopsy with 19 gauge needle
Study NCT01815606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy with 25 gauge needle
Description: biopsy with 25 gauge needle
Study NCT03813186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 + Day 2 Food
Description: ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
Study NCT03813186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 + Day 4 Food
Description: ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
Study NCT01765244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anterior lamellar nanostructured artificial human cornea.
Description: Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
Study NCT01765244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane transplantation
Description: Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
Study NCT01021761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Study NCT01021761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Study NCT01021761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac
Description: drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Study NCT02381301 — intervention group
Intervention type: BIOLOGICAL
Intervention: Venous blood sampling prior to CCTA.
Study NCT05102825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1H and Xe-129 MRI
Description: Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
Study NCT04395092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K-NK002
Description: K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety.
Study NCT04395092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3.
Study NCT04395092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HaploBMT
Description: Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
Study NCT01576276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Integrated MR-PET scan
Description: Integrated MR-PET scan using \[11C\]diprenorphine
Study NCT01576276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 3 administrations of ketorolac over course of study
Study NCT02349464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized Preterm Infant/Mother Dyad Lactation Support
Description: Mother will receive home equipment and pediatric clinic lactation support.
Study NCT01044342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsule; single oral dose
Study NCT01044342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsule, single oral dose
Study NCT01044342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: capsule, single oral dose
Study NCT02395640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50mg/m2 ivgtt d1
Study NCT02395640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT02395640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02395640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 po d1-14
Study NCT02395640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 po d1-14
Study NCT04342741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter cervical ripening
Description: Participants were assessed when labour was established or the following morning.
Study NCT03578458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: subjects will install a mobile app for use
Description: novel mobile application
Study NCT01048112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campylobacter jejuni strain CG8421
Description: Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
Study NCT01048112 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Campylobacter jejuni strain CG8421
Description: Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
Study NCT03273465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Fecal transplantation administered orally via frozen capsules.
Study NCT03273465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal transplantation
Description: Fecal transplantation administered orally via frozen capsules.
Study NCT03667872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral implantation of DBS system to Habeluna
Description: Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
Study NCT03627377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Description: Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
Study NCT03356119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid device
Description: The contraceptive implants of the subjects in this arm are removed by the new IMD.
Study NCT02021136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebel Reliever
Description: Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
Study NCT02021136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual antalgic treatment + physical exercises recommendations
Study NCT04331067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: -Given standard of care
Study NCT04331067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Given standard of care
Study NCT04331067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: -Given standard of care
Study NCT04331067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: -Given standard of care
Study NCT04331067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: -Given standard of care
Study NCT04331067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Given standard of care
Study NCT04331067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: -Will be provided by Bristol Myers Squibb
Study NCT04331067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor biopsy
Description: -Baseline, week 5, surgery, and at time of relapse (optional)
Study NCT04331067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Baseline, week 5, surgery, and at time of relapse (optional)
Study NCT04331067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow
Description: -Time of port placement (baseline), time of surgery, and time of recurrence (optional)